ReviewBiological psychiatry2011
Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations.
Review in Biological psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Translating neurophysiological biomarkers into clinical tools: A psychometric blueprint illustrated with the error-related negativity.The American psychologist · 2025Review
- The psychometric upgrade psychophysiology needs.Psychophysiology · 2024Review
- From Computation to Clinic.Biological psychiatry global open science · 2023Review
- Importance of test-retest reliability for promoting fMRI based screening and interventions in major depressive disorder.Translational psychiatry · 2021Article
- Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms.Cerebral cortex (New York, N.Y. : 1991) · 2019Article
- Neuroimaging of individual differences: A latent variable modeling perspective.Neuroscience and biobehavioral reviews · 2019Review
- Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias.Journal of abnormal psychology · 2016Article
- Building a Science of Individual Differences from fMRI.Trends in cognitive sciences · 2016Review
- Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study.Human brain mapping · 2015Article
- Article
- Psychotherapy and Neuroimaging.Focus (American Psychiatric Publishing) · 2014Article
- Model specification and the reliability of fMRI results: implications for longitudinal neuroimaging studies in psychiatry.PloS one · 2014Article
- Clinical utility of the N-back task in functional neuroimaging studies of working memory.Journal of clinical and experimental neuropsychology · 2014Article
- Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) on Brain Functional Marker of Auditory Hallucinations in Schizophrenia Patients.Brain sciences · 2013Article
- Functional neuroimaging of treatment effects in psychiatry: methodological challenges and recommendations.The International journal of neuroscience · 2012Review
- Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies.Journal of magnetic resonance imaging : JMRI · 2012Review
- Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development.Schizophrenia bulletin · 2012Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
The first phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICs) initiative focused on the identification of cognitive constructs from human and animal neuroscience that were relevant to understanding cognitive deficits in schizophrenia, as well as promising task paradigms that could be used to assess these constructs behaviorally. The current phase of CNTRICs has the goal of expanding this initial work by including measures of brain function that can augment these behavioral tasks as biomarkers to be used in drug development processing. Here we review many of the psychometric issues that need to be addressed regarding the development and inclusion of such methods in the drug development process. In addition, we review quality assurance concerns, issues associated with multicenter trials, concerns associated with potential pharmacologic confounds on imaging measures, as well as power and analysis considerations. Although review is couched in the context of the use of biomarkers for treatment studies in schizophrenia, we believe the issues and suggestions included are relevant to the entire range of neuropsychiatric disorders as well as to a wide range of imaging modalities (i.e., functional magnetic resonance imaging, positron emission tomography, event-related potentials, electroencephalography, transcranial magnetic stimulation, near infrared spectroscopy, etc.) and are relevant to both pharmacologic and psychological intervention approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.